New perspectives in clinical oncology from angiogenesis research

European Journal of Cancer Part A

Volumn 32, Issue 14, 1996, Pages 2534-2539

  Folkman, J ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; CANCER RESEARCH; CELL PROLIFERATION; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

EID: 0030500450     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00423-6     Document Type: Article

References (60)

1. 1. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79, 315-328.
2. 2. Warren BA, Chauvin WJ, Philips J. Blood-borne tumor emboli and their adherence to vessel walls. In Day SB, Myers WPL, Stansly P, Garattini S, Lewis MG, eds. Progress in Cancer Research and Therapy. New York, Raven Press, 1977, 185-197.
3. 3. Sugarbaker EV, Thornthwaite J, Ketcham AS. Inhibitory effect of a primary tumor on metastases. In Day SB, Myers WPL, Stansly P, Garattini S, Lewis MG, eds. Progress in Cancer Research and Therapy. New York, Raven Press, 1977, 227-240.
4. 4. Clark WH Jr, Elder DE, Guerry DIV, et al. Model predicting survival in stage 1 melanoma based on tumor progression. J Natl Cancer Inst 1989, 81, 1893-1904.
5. 5. Woodruff M. The Interactions of Cancer and the Host. Grune and Stratton, New York, 1980.
6. 6. Marie P, Clunet J. Frequence des metastases viscerales chez les souris cancereuses apres ablation chirurgicale de leur tumeur. Bull Assoc Franc l'Etude Cancer 1910, 3, 19-23.
7. 7. Tyzzer EE. Factors in the production and growth of tumor metastases. J Med Res 1913, 28, 309-333.
8. 8. Gorelik E. Concomitant tumor immunity and the resistance to a second tumor challenge. Adv Cancer Res 1983, 39, 71-120.
9. 9. Prehn RT. The inhibition of tumor growth by tumour mass. Cancer Res 1991, 51, 2-4.
10. 10. Prehn RT. Two competing influences that may explain concomitant tumor resistance. Cancer Res 1993, 53, 3266-3269.
11. 11. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during transition from hyperplasia to neoplasia. Nature 1989, 339, 58-61.
12. 12. Parangi S, O'Reilly M, Christofori G, et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 1996, 93, 2002-2007.
13. 13. Christofori G, Naik P, Hanahan D. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 1995, 9, 1760-1770.
14. 14. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86, 353-364.
15. 15. Rastinejad F, Polverini P, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989, 56, 345-355.
16. 16. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265, 1582-1584.
17. 17. Meltzer A. Dormancy and breast cancer. J Surg Oncol 1990, 43, 181-188.
18. 18. Wheelock EF, Weinhold KJ, Levich J. The tumor dormant state. Adv Cancer Res 1981, 34, 107-140.
19. 19. Woodruff M. Interactions of cancer and host. The Walter Hubert Lecture. Br J Cancer 1982, 46, 313-322.
20. 20. Vitetta ES, Uhr JW. Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. Cancer Res 1994, 54, 5301-5309.
21. 21. Noble RIL, Hoover L. A classification of transplantable tumors in NB rats controlled by estrogen from dormancy to autonomy. Nature Med 1975, 35, 2935-2941.
22. 22. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995, 1, 149-153.
23. 23. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 1996, 2, 689-692.
24. 24. White E, Cipriani R, Sabattini P, Demon A. Adenovirus E1B 19-kilodalton protein overcomes the cytotoxicity of E1A proteins. J Virol 1991, 65, 2968-2978.
25. 25. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992, 69, 119-128.
26. 26. Dedera DA, Waller EK, LeBrun DP, et al. Chimeric homeobox gene E2A-PBX1 induces proliferation, apoptosis and malignant lymphomas in transgenic mice. Cell 1993, 74, 833-843.
27. 27. Harrington EA, Fanidi A, Evan GI. Oncogenes and cell death. Curr Opin Gen Dev 1994, 4, 120-129.
28. 28. Folkman J. Tumor angiogenesis. In Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer. Philadelphia, W.B. Saunders, 1995, 206-232.
29. 29. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995, 1, 27-31.
30. 30. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994, 12, 1272-1280.
31. 31. Yuhas JM, Pazmino NH. Inhibition of subcutaneously growing line 1 carcinomas due to metastatic spread. Cancer Res 1974, 34, 2005-2010.
32. 32. Demicheli R, Terenziani M, Valagussa P, Moliterni A, Zambetti M, Bonadonna G. Local recurrences following mastectomy: support for the concept of tumor dormancy. J Natl Cancer Inst 1994, 86, 45-48.
33. 33. Nanus DM, Schmitz-Drager BJ, Motzer RJ, et al. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 1993, 85, 1597-1599.
34. 34. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994, 86, 356-361.
35. 35. Ingber DM, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990, 348, 555-557.
36. 36. Brem H, Folkman J. Analysis of experimental antiangiogenic therapy. J Pediatr Surg 1993, 28, 445-451.
37. 37. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995, 333, 1757-1763.
38. 38. Folkman J. Fighting cancer by attacking its blood supply. Scientific American 1996, 275, 150-154.
39. 39. Nicosia RF, Tchao R, Leighton J. Interactions between newly formed endothelial channels and carcinoma cells in plasma clot culture. Clin Exp Metast 1986, 4, 91-104.
40. 40. Hamada J, Cavanaugh PG, Lotan O, Nicolson GI. Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. Br J Cancer 1992, 66, 349-354.
41. 41. Rak JW, Hegmann EJ, Lu C, Kerbel RS. Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression. J Cell Physiol 1994, 159, 245-255.
42. 42. Folkman J. Tumor Angiogenesis. In Holland JF, Frei E, Bast R, Kufe D, Morton D, Weichselbaum R, eds. William & Wilkins, Baltimore, Maryland. Cancer Medicine, in press.
43. 43. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer agents. BioEssays 1991, 13, 31-36.
44. 44. Teicher BA, Holden SA, Ara G, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994, 57, 920-925.
45. 45. Belotti D, Nicoletti I, Vergani V, et al. Paclitaxel (Taxol), a microtubule affecting drug, inhibits tumor induced angiogenesis. Proc Am Assoc Cancer Res 1996, 37, 57 (abstract 397).
46. 46. Oktaba AMC, Hunter WL, Arsenault AL. Taxol: a potent inhibitor of normal and tumor-induced angiogenesis. Proc Am Assoc Cancer Res 1995, 36, 454 (abstract 2707).
47. 47. Steiner R, Weisz P, Langer R, eds. Angiostatic activity of anti-cancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay. In Angiogenesis: Key Principles - Science -Technology - Medicine. Basel, Birkhauser Verlag, Switzerland, 1992, 449-454.
48. 48. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Folkman J. Spectrum of tumor angiogenesis in bone marrow of children with acute lymphoblastic leukemia. Lab Invest 1995, 72, A141.
49. 49. Ribatti D, Vacca A, Bertossi M, De Benedictis G, Roncali L, Dammacco F. Angiogenesis induced by B-cell non-Hodgkin's lymphomas. Lack of correlation with tumor malignancy and immunologic phenotype. Anticancer Res 1990, 10, 401-406.
50. 50. Smith-McCune KK, Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 1994, 54, 800-804.
51. 51. Ziehe M, Gullino PM. Angiogenesis and neoplastic progression in vitro. J Natl Cancer Inst 1982, 69, 483-487.
52. 52. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med (Erratum N Engl J Med 1994, 330, 300) 1992, 326, 1456-1463.
53. 53. Folkman J, Langer R, Linhardt R, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983, 221, 719-725.
54. 3 for angiogenesis. Science 1994, 264, 569-571.
55. 55. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metast Rev 1990, 3, 267-282.
56. 56. Jain RK. Barriers to drug delivery in solid tumors. Scientific American 1994, 1, 58-65.
57. 57. Modzelewski R, Davies P, Watkins SC, Auerbach R, Chang M-J, Johnson CS. Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma. Cancer Res 1994, 54, 336-339.
58. 58. Folkman J. Tumor angiogenesis and tissue factor. Nature Med 1996, 2, 167-168.
59. 59. Folkman J. Angiogenesis and metastatic growth. Adv Oncol 1996, 12, 3-7.
60. 60. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato R. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors α-methoxyestradiol and taxol. Cancer Res, in press.